Delivery of therapeutic radioisotopes using nanoparticle platforms: Potential benefit in systemic radiation therapy

Nanotechnology, Science and Applications

Volumn 3, Issue 1, 2010, Pages 159-170

  Zhang, Longjiang ^a,b   Chen, Hongwei ^a   Wang, Liya ^a   Liu, Tian ^a,c   Yeh, Julie ^a   Lu, Guangming ^b   Yang, Lily ^a,c   Mao, Hui ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c EMORY UNIVERSITY   (United States)

Author keywords

Cancer; Delivery; Nanoparticle; Radiation therapy; Radioisotope

Indexed keywords

AMINO TERMINAL FRAGMENT CY5.5 CONJUGATE; AMINO TERMINAL FRAGMENT CY5.5 IRON OXIDE NANOPARTICLE; ANTIBODY CONJUGATE; ANTIBODY CONJUGATED RADIOISOTOPE; ARGINYLGLYCYLASPARTIC ACID; CHIMERIC L6 MONOCLONAL ANTIBODY IN 111; COPPER 64 RADIOLABELED FOLATE CONJUGATED SHELL CROSS LINKED NANOPARTICLE; FOLATE RECEPTOR; FOLIC ACID; GALLIUM 67; IBRITUMOMAB TIUXETAN; IODINE 123; IODINE 125; IODINE 131; IRON OXIDE NANOPARTICLE; LIPOSOME; MACROGOL; MAGNETIC NANOPARTICLE; MONOCLONAL ANTIBODY; NANOPARTICLE; POLYGLACTIN; RADIOIMMUNONANOPARTICLE; RADIOISOTOPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN MONOCLONAL ANTIBODY I 131; VASCULOTROPIN RECEPTOR 2; YTTRIUM 90; YTTRIUM 90 LABELED FLK MONOCLONAL ANTIBODY;

ALPHA RADIATION; ALTERNATING MAGNETIC FIELD; AUGER; B CELL LYMPHOMA; BINDING AFFINITY; BIOCOMPATIBILITY; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL DEATH; CHEMICAL MODIFICATION; COLON ADENOCARCINOMA; CONJUGATION; CROSS LINKING; DEGRADATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RETENTION; DRUG TARGETING; DRUG UPTAKE; ELECTRON; ELECTRON RADIATION; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONALIZATION; GAMMA RADIATION; HUMAN; HYPERTHERMIC THERAPY; INTERNALIZATION; LIGAND BINDING; LIVER CANCER; MAGNETIC FIELD; MELANOMA; NANOPROBE; NEUTRON CAPTURE THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; RADIATION ENERGY; RADIOIMMUNOTHERAPY; RADIOISOTOPE DECAY; REVIEW; SURFACE CHARGE;

EID: 78650699653     PISSN: None     EISSN: 11778903     Source Type: Book Series    
DOI: 10.2147/NSA.S7462     Document Type: Review

References (74)

1. Jemal A, Siegel R, Ward E, et al. 2008. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
2. Jarzyna PA, Skajaa T, Gianella A, et al. Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials. 2009;30:6947-6954.
3. Peng X, Qian X, Mao H, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomed. 2008;3:311-321.
4. Yang L, Peng X, Wang A, et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res. 2009;15:4722-4732.
5. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol Pharm. 2005;2:357-366.
6. Bae Y, Diezi TA, Zhao A, Kwon GS. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J Control Release. 2007;122:324-330.
7. Lee H, Lee E, Kim K, Jang NK, Jeong YY, Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc. 2006;128:7383-7389.
8. Korb L. Radiotherapy for the palliation of prostate cancer. Semin Surg Oncol. 2000;18:75-79.
9. Hartmann F, Horak EM, Garmestani K, et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res. 1994;54:4362-4370.
10. Kennel SJ, Stabin M, Roeske JC, et al. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res. 1999;151:244-256.
11. Ballangrud AM, Yang WH, Charlton DE, et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 2001;61:2008-2014.
12. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1987;13:1767-1773.
13. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693-713.
14. Salvatori M, Indovinal L, Mansi L. Targeted t-particle therapy: a clinical overview. Current Radiopharmaceuticals. 2008;1:251-253.
15. Zalutsky MR. Targeted a-particle therapy of microscopic disease: providing a further rationale for clinical investigation. J Nucl Med. 2006;47:1238-1240.
16. Mühlhausen U, Schirrmacher R, Piel M, et al. Synthesis of 131Ilabeled glucose-conjugated inhibitors of O6-methylguanine-DNA methyltransferase (MGMT) and comparison with nonconjugated inhibitors as potential tools for in vivo MGMT imaging. J Med Chem. 2006;49:263-272.
17. Schipper ML, Riese CG, Seitz S, et al. Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo. Eur J Nucl Med Mol Imaging. 2007;34:638-650.
18. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted a-particle therapy. J Nucl Med. 2005;46:199S-204S.
19. Mitra A, Nan A, Line BR, et al. Nanocarriers for nuclear imaging and radiotherapy of cancer. Current Pharmaceutical Design. 2006;12:4729-4749.
20. Saravanakumar G, Kim K, Park JH, et al. Current status of nanoparticlebased imaging agents for early diagnosis of cancer and atherosclerosis. J Biomed Nanotechno. 2009;5:20-35.
21. Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discovery Today. 2004;9:219-228.
22. Li L, Wartchow CA, Danthi SN, et al. A novel antiangiogenesis therapy using an integrin or anti-FLK-1 antibody cotated 90Y-labeled nanoparticles. Int J Radiation Oncology Biol Phys. 2004;58:1215-1227.
23. DeNardo SJ, DeNardo GL, Miers LA, et al. Development of tumor targeting bioprobes (111In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res. 2005;11:7087S-7092S.
24. Chen J, Wu H, Han D, et al. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Letters. 2006;231:169-175.
25. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9:257-288.
26. Qian X, Peng XH, Ansari DO, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol. 2008;26:83-90.
27. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995-4021.
28. Veiseh O, Sun C, Gunn J, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Letters. 2005;5:1003-1008.
29. Xie J, Xu C, Kohler Y, et al. Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv Mater. 2007;19:3163-3166.
30. Veiseh O, Sun C, Fang C, et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the bloodbrain barrier. Cancer Res. 2009;69:6200-6207.
31. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60:1252-1265.
32. Briley-Saebo K, Bjørnerud A, Grant D, et al. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res. 2004;316:315-323.
33. Fujita T, Nishikawa M, Ohtsubo Y, et al. Control of in-vivo fate of albumin derivatives utilizing combined chemical modification. J Drug Target. 1994;2:157-165.
34. Kairdolf BA, Mancini MC, Smith AM, et al. Minimizing nonspecific cellular binding of quantum dots with hydroxyl-derivatizied surface coatings. Anal Chem. 2008;80:3029-3034.
35. Ladd J, Zhang Z, Chen S, et al. Zwitterionic polymers exhibiting high resistance to nonspecific protein adsorption from human serum and plasma. Biomacromolecules. 2008;9:1357-1361.
36. Breus VV, Heyes CD, Tron K, et al. Zwitterionic Biocompatible Quantum Dots for Wide pH Stability and Weak Nonspecific Binding to Cells. ACS Nano. 2009;3:2573-2580.
37. Yang W, Zhang L, Wang S, et al. Functionalizable and ultra stable nanoparticles coated with zwitterionic poly(carboxybetaine) in undiluted blood serum. Biomaterials. 2009;30:5617-5621.
38. Chen H, Wu X, Duan H, et al. Biocompatible polysiloxane-containing diblock copolymer PEO-b-P dMPS for coating magnetic nanoparticles. ACS Applied Materials and Interfaces. 2009;1:2134-2140.
39. Panyam J, Zhou WZ, Prabha S, et al. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16:1217-1226.
40. Nasongkla N, Bey E, Ren J, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Letters. 2006;6:2427-2430.
41. Liu X, Wang Y, Nakamura K, et al. Auger radiation - induced, antisensemediated cytotoxicity of tumor cells using a 3-component streptavidindelivery nanoparticle with 111In. J Nucl Med. 2009;50:582-590.
42. Wang MD, Shin DM, Simon JW, et al. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther. 2007;7:833-837.
43. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews. 2004;56:1649-1659.
44. van Vlerken LE, Vyas TK, Amiji MM. Poly (ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharmaceutical Research. 2007;24:1405-1414.
45. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65:5317-5324.
46. Weissleder R, Kelly K, Sun EY, et al. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23:1418-1423.
47. Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007;2:47-52.
48. Yang L, Mao H, Wang YY, et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small. 2009;5:235-243.
49. Zhang CF, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007;67:1555-1562.
50. Cai WB, Chen XY. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nature Protocols. 2008;3:89-96.
51. Antony AC. Folate receptors. Annu Rev Nutr. 1996;16:501-512.
52. Ke CY, Mathias CJ, Green MA. Folate-receptor-targeted radionuclide imaging agents. Adv Drug Deliv Rev. 2004;56:1143-1160.
53. Das M, Mishra D, Dhak P, et al. Biofunctionalized, phosphonategrafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging. Small. 2009;5:2883-2893.
54. Thomas M, Kularatne SA, Qi L, et al. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann N Y Acad Sci. 2009;1175:32-39.
55. Setua S, Menon D, Asok A, et al. Folate receptor targeted, rare-earth oxide nanocrystals for bi-modal fluorescence and magnetic imaging of cancer cells. Biomaterials. 2010;31:714-729.
56. Rossin R, Pan D, Qi K, et al. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biological evaluation. J Nucl Med. 2005;46:1210-1218.
57. Alexiou H, Jurgons R, Schmid RJ, et al. Magnetic drug targetingbiodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Targeting. 2003;11:139-149.
58. Raylman RR, Wahl RL. Magnetically enhanced radionuclide therapy. J Nucl Med. 1994;35:157-163.
59. Streffer C. The biological basis for tumor therapy by hyperthermia and radiation. In: Streffer J, editor. Hyperthermia and The Therapy of Malignant Tumors. Berlin: Springer; 1987.
60. Moroz P, Jones SK, Gray BN. Magnetically mediated hyperthermia: Current status and future directions. Int J Hyperthermia. 2003;8:267-284.
61. Natarajan A, Xiong C, Gruettner C, et al. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biotherapy Radiopharmaceuticals. 2008;23:82-91.
62. Natarajan A, Gruettner C, Ivkov R, et al. Nanoferrite particle based radioimmunonanoparticles: binding af?nity and in vivo pharmacokinetics. Bioconjugate Chem. 2008;19:1211-1218.
63. Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomed. 2008;3:181-199.
64. Azab AK, Srebnik M, Doviner V, et al. Targeting normal and neoplastic tissues in the rat jejunum and colon with boronated, cationic acrylamide copolymers. J Control Release. 2005;106:14-25.
65. Yinghuai Z, Peng AT, Carpenter K, et al. Substituted carboraneappended water-soluble single-wall carbon nanotubes: new approach to boron neutron capture therapy drug delivery. J Am Chem Soc. 2005;127:9875-9880.
66. Mortensena MW, Sørensenb PG, Bjorkdahl O, et al. Preparation and characterization of Boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy. Applied Radiation Isotopes. 2006;64:315-324.
67. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta. 2009;1788:2259-2266.
68. Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci. 2006;27:27-36.
69. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials. 2003;24:1001-1011.
70. Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-gycine-aspartic (RGD) - conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008;49:1371-1379.
71. He X, Nie H, Wang K, Tan W, Wu X, Zhang P. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. Anal Chem. 2008;80:9597-9603.
72. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117:379-387.
73. Jacene HA, Filice R, Kasecamp W, et al. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009;50:8-17.
74. Esmaeli B, McLaughlin P, Pro B, et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009;20:709-714.